Story Highlights
- The DOJ’s civil rights division sent Yale a letter on May 14 concluding its year-long investigation found ongoing racial discrimination in admissions
- Admitted Black and Hispanic applicants at Yale had lower average GPAs and MCAT scores than admitted White and Asian applicants over the past three cycles
- Yale said it would review the letter and expressed confidence in its admissions process; no immediate legal action was announced
What Happened
The U.S. Department of Justice sent a formal letter to the Yale School of Medicine on Thursday, May 14, informing the institution that a year-long federal investigation had concluded it was illegally discriminating against applicants based on race, in violation of the Supreme Court’s landmark 2023 ruling in Students for Fair Admissions v. Harvard. The letter, issued by the DOJ’s civil rights division, accused Yale of continuing to use race and national origin as factors in its admissions decisions despite the court’s clear prohibition.
The investigation reviewed Yale’s internal documents, data, and correspondence and found that admissions personnel had continued to receive and apply a holistic review procedure that incorporated racial considerations. The DOJ letter specifically cited Yale’s internal policies and email correspondence from leadership as evidence of “intent to use race in admissions decisions despite the Harvard ruling.” The department concluded that this discrimination was ongoing, not merely historical.
Applicant-level data included in the letter showed that admitted Black and Hispanic students had lower average GPA and MCAT scores than admitted White and Asian students over the most recent three admissions cycles. The DOJ acknowledged that these figures do not account for all factors considered during holistic review, but argued that the patterns demonstrated racially disparate treatment. According to the Association of American Medical Colleges, Yale’s 2023-2024 enrollment included 175 White students, 157 Asian students, 44 Black students, and 26 Hispanic students.
Karen Peart, Yale’s associate vice president for communications, said in a statement that the university would “carefully review” the DOJ’s letter and expressed confidence in the rigor of its admissions process. Yale did not concede any wrongdoing.
The action follows a similar letter sent to the UCLA David Geffen School of Medicine on May 6, and builds on a DOJ lawsuit against UCLA that was filed in January. The Trump administration had also previously joined a private lawsuit against UCLA filed by Do No Harm, an organization that advocates against diversity-based practices in medicine.
Why It Matters
The Supreme Court’s 2023 decision outlawing race-conscious admissions in higher education was widely understood as a sweeping prohibition on affirmative action at colleges and universities. However, the ruling’s application to graduate professional schools — particularly medical schools — and the question of what constitutes a race-neutral admissions process have remained areas of legal uncertainty and institutional debate.
By targeting two prominent medical schools within eight days, the DOJ is signaling that the Trump administration intends to aggressively enforce the court’s ruling beyond undergraduate admissions. The action affects not only Yale and UCLA but sends a message to every medical school in the country that holistic admissions procedures that yield racially diverse classes may be subject to federal scrutiny regardless of whether explicit racial categories are applied.
The administration’s legal theory is notable and contested. As UPI reported, the DOJ has embraced “disparate impact” reasoning — arguing that even facially race-neutral admissions policies are illegal if they produce racially disparate outcomes. That logic creates a difficult bind for institutions, as Georgetown Law’s Andrew Twinamatsiko explained: schools that actively pursue diversity can be accused of discrimination, while schools that produce diverse outcomes through race-neutral means may also face scrutiny for those outcomes.
This is not the first time Yale has faced federal attention on this issue. In 2020, during Trump’s first term, the Justice Department sued Yale over discrimination against White and Asian applicants in undergraduate admissions. That case was dropped shortly after President Biden took office. The current action suggests the administration views Yale as a repeat offender and is prepared to escalate.
Economic and Global Context
Medical schools occupy a uniquely sensitive position in American society. Their admissions decisions have direct consequences for the composition of the physician workforce, which in turn affects health outcomes, healthcare access in underserved communities, and the long-term diversity of medical research. The debate over who gets into medical school is therefore not merely an institutional legal question — it is a public health policy question with measurable effects on patient care across the country.
The Trump administration has pursued a parallel set of actions in recent months that reinforce this campaign. An executive order signed on Trump’s first day in office targeted DEI programs across federal funding streams. It terminated research grants mentioning health disparities, and another executive order pressured the primary medical school accrediting body, which subsequently removed requirements to teach health equity as part of curricula.
The convergence of these actions — grant terminations, curriculum changes, and now direct admissions enforcement — represents a comprehensive restructuring of the incentives and constraints governing medical education. Institutions that depended on federal research funding while also pursuing diversity goals now face pressure on multiple fronts simultaneously.
Implications
For Yale and other elite medical schools, the DOJ finding presents a stark choice: formally abandon holistic admissions procedures that have historically produced diverse incoming classes, or face the possibility of federal litigation and the potential loss of federal funding. Neither path is without serious consequence. The former risks a significant reduction in the diversity of the physician pipeline; the latter risks institutional financial damage and reputational harm.
For prospective medical students, the policy environment is shifting in ways that may alter who applies, who is admitted, and ultimately who practices medicine in the United States. Asian and White applicants who believe they were disadvantaged by prior admissions practices may view the DOJ’s action as a long-overdue correction. Black and Hispanic applicants, and the medical schools that have worked to increase their representation, see a significant threat to decades of progress.
For policymakers and legal observers, the DOJ’s application of disparate impact theory against institutions accused of favoring minority groups represents a significant and philosophically provocative inversion of how that legal tool has traditionally been used. Courts will ultimately determine whether that argument holds, and the Yale and UCLA cases may well end up before the Supreme Court.
Sources
“DOJ accuses Yale and UCLA medical schools of discriminating against white and Asian applicants”
